News Center
Shanghai Cell Therapy Group Tanhua "2022 Top 100 Future Healthcare China Innovative Biomedical List"
2022-06-17
The list of the top 100 future medical care series, launched by Arterial Network and Eggshell Research Institute, aims to select Chinese innovative medical enterprises representing future medical care and discover the core strength of my country's future medical industry. The list is based on 17 indicators such as enterprise valuation, growth, company patent status, product development, core team, partners, industry structure, and corporate reputation. Investment weather vane.
This year is the sixth year of the list. Based on the perspective of "China Story", the conversation takes place in China's local innovation and the new solutions brought by China's local innovation to the world's problems.
As the world's only comprehensive medical and biopharmaceutical group in the field of cell therapy, the group has won 269 patent applications, 59 patent authorizations, 60 international PCT inventions, and 11 US patents. High recognition of strength.
Shanghai Cell Therapy Group was established in 2013. Focusing on tumor treatment and anti-aging research, it has formed a three-in-one industry closed-loop chain of "cell health (cryopreservation), cell drug (R&D), and cell medicine (genetic testing and clinical research applications)." It has opened up the entire industrial chain of genetic testing, cell collection, cryopreservation, cell drug research and development, production, and clinical transformation and application, and is committed to the establishment of a large-scale cell industry system.
Recently, the group is also developing new transposon technology, non-viral vector CAR-T technology, delivery vector, artificial intelligence technology of nanobody, mRNA modified nucleotide and delivery vector with completely independent intellectual property rights, and progenitor cell (GDP) unlimited. Breakthroughs have been made in many aspects such as self-renewal.
The third place on the list this time is an honor and a driving force. It will urge Baize people to continue to work hard on the road of benefiting the common people and improving China's medical career, and to realize the "Baize Plan" as soon as possible: 60% of cancer patients' tumors will subside within 10 years, and 60% of the common people will be able to afford it. This technology; 30 years, more people live healthy and beautiful to their natural lifespan.
Contact Info
ADD: No. 9 Yanzheng West Avenue, Wujin District, Changzhou City, Jiangsu Province
Copyright© 2022 Jiangsu Baize Cell Biotechnology Co., Ltd Powered by www.300.cn This website already supports IPV6 Seo
Online Message